#ASH22: Lil­ly’s Loxo spells out BTK da­ta as it eyes BeiGene, Ab­b­Vie/J&J and As­traZeneca

NEW OR­LEANS — Eli Lil­ly’s Loxo On­col­o­gy unit showed up at this year’s Amer­i­can So­ci­ety of Hema­tol­ogy con­fer­ence with da­ta in mul­ti­ple sub­sets of pa­tients on pir­to­bru­ti­nib, its non-co­va­lent BTK in­hibitor in a field stacked with com­peti­tors.

Loxo start­ed its con­fer­ence pre­sen­ta­tions with da­ta on rare sub­sets not in­clud­ed in the ex­pect­ed ac­cel­er­at­ed ap­proval de­ci­sion ear­ly next year for pir­to­bru­ti­nib, for pre-treat­ed man­tle cell lym­phoma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER